scispace - formally typeset
Search or ask a question
Author

Marco Lucchi

Bio: Marco Lucchi is an academic researcher from University of Pisa. The author has contributed to research in topics: Lung cancer & Thymoma. The author has an hindex of 47, co-authored 199 publications receiving 9227 citations.
Topics: Lung cancer, Thymoma, Cancer, Survival rate, Medicine


Papers
More filters
Journal ArticleDOI
Peter Goldstraw1, Kari Chansky, John Crowley, Ramón Rami-Porta2, Hisao Asamura3, Wilfried Ernst Erich Eberhardt4, Andrew G. Nicholson1, Patti A. Groome5, Alan Mitchell, Vanessa Bolejack, David Ball6, David G. Beer7, Ricardo Beyruti8, Frank C. Detterbeck9, Wilfried Eberhardt4, John G. Edwards10, Françoise Galateau-Salle11, Dorothy Giroux12, Fergus V. Gleeson13, James Huang14, Catherine Kennedy15, Jhingook Kim16, Young Tae Kim17, Laura Kingsbury12, Haruhiko Kondo18, Mark Krasnik19, Kaoru Kubota20, Antoon Lerut21, Gustavo Lyons, Mirella Marino, Edith M. Marom22, Jan P. van Meerbeeck23, Takashi Nakano24, Anna K. Nowak25, Michael D Peake26, Thomas W. Rice27, Kenneth E. Rosenzweig28, Enrico Ruffini29, Valerie W. Rusch14, Nagahiro Saijo, Paul Van Schil23, Jean-Paul Sculier30, Lynn Shemanski12, Kelly G. Stratton12, Kenji Suzuki31, Yuji Tachimori32, Charles F. Thomas33, William D. Travis14, Ming-Sound Tsao34, Andrew T. Turrisi35, Johan Vansteenkiste21, Hirokazu Watanabe, Yi-Long Wu, Paul Baas36, Jeremy J. Erasmus22, Seiki Hasegawa24, Kouki Inai37, Kemp H. Kernstine38, Hedy L. Kindler39, Lee M. Krug14, Kristiaan Nackaerts21, Harvey I. Pass40, David C. Rice22, Conrad Falkson5, Pier Luigi Filosso29, Giuseppe Giaccone41, Kazuya Kondo42, Marco Lucchi43, Meinoshin Okumura44, Eugene H. Blackstone27, F. Abad Cavaco, E. Ansótegui Barrera, J. Abal Arca, I. Parente Lamelas, A. Arnau Obrer45, R. Guijarro Jorge45, D. Ball6, G.K. Bascom46, A. I. Blanco Orozco, M. A. González Castro, M.G. Blum, D. Chimondeguy, V. Cvijanovic47, S. Defranchi48, B. de Olaiz Navarro, I. Escobar Campuzano2, I. Macía Vidueira2, E. Fernández Araujo49, F. Andreo García49, Kwun M. Fong, G. Francisco Corral, S. Cerezo González, J. Freixinet Gilart, L. García Arangüena, S. García Barajas50, P. Girard, Tuncay Göksel, M. T. González Budiño51, G. González Casaurrán50, J. A. Gullón Blanco, J. Hernández Hernández, H. Hernández Rodríguez, J. Herrero Collantes, M. Iglesias Heras, J. M. Izquierdo Elena, Erik Jakobsen, S. Kostas52, P. León Atance, A. Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles53, L. De Esteban Júlvez53, M. Mariñán Gorospe, Brian C. McCaughan15, Catherine J. Kennedy15, R. Melchor Íñiguez54, L. Miravet Sorribes, S. Naranjo Gozalo, C. Álvarez de Arriba, M. Núñez Delgado, J. Padilla Alarcón, J. C. Peñalver Cuesta, Jongsun Park16, H. Pass40, M. J. Pavón Fernández, Mara Rosenberg, Enrico Ruffini29, V. Rusch14, J. Sánchez de Cos Escuín, A. Saura Vinuesa, M. Serra Mitjans, Trond Eirik Strand, Dragan Subotic, S.G. Swisher22, Ricardo Mingarini Terra8, Charles R. Thomas33, Kurt G. Tournoy55, P. Van Schil23, M. Velasquez, Y.L. Wu, K. Yokoi 
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.

2,826 citations

Journal ArticleDOI
William D. Travis1, Hisao Asamura2, Alexander A. Bankier3, Mary Beth Beasley4, Frank C. Detterbeck5, Douglas B. Flieder6, Jin Mo Goo7, Heber MacMahon8, David P. Naidich9, Andrew G. Nicholson10, Charles A. Powell, Mathias Prokop11, Ramón Rami-Porta12, Valerie W. Rusch1, Paul Van Schil, Yasushi Yatabe, Peter Goldstraw10, David Ball13, David G. Beer14, Ricardo Beyruti15, Vanessa Bolejack16, Kari Chansky16, John Crowley16, Wilfried Eberhardt17, John G. Edwards18, Françoise Galateau-Salle19, Dorothy Giroux16, Fergus V. Gleeson20, Patti A. Groome21, James Huang1, Catherine Kennedy22, Jhingook Kim23, Young Tae Kim24, Laura Kingsbury16, Haruhiko Kondo25, Mark Krasnik26, Kaoru Kubota27, Antoon Lerut28, Gustavo Lyons29, Mirella Marino, Edith M. Marom30, Jan P. van Meerbeeck31, Alan Mitchell16, Takashi Nakano32, Anna K. Nowak33, Michael D Peake34, Thomas W. Rice35, Kenneth E. Rosenzweig36, Enrico Ruffini37, Nagahiro Saijo, Jean-Paul Sculier38, Lynn Shemanski16, Kelly G. Stratton16, Kenji Suzuki39, Yuji Tachimori40, Charles F. Thomas41, William D. Travis1, Ming-Sound Tsao42, Andrew T. Turrisi43, Johan Vansteenkiste28, Hirokazu Watanabe, Yi-Long Wu, Paul Baas44, Jeremy J. Erasmus30, Seiki Hasegawa32, Kouki Inai45, Kemp H. Kernstine46, Hedy L. Kindler8, Lee M. Krug1, Kristiaan Nackaerts28, Harvey I. Pass9, David C. Rice30, Conrad Falkson21, Pier Luigi Filosso37, Giuseppe Giaccone47, Kazuya Kondo48, Marco Lucchi49, Meinoshin Okumura50, Eugene H. Blackstone35 
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.

431 citations

Journal Article
TL;DR: Evaluation of neoangiogenesis and of certain growth factors, such as AR, can be useful in addition to conventional pathological staging to select high-risk NSCLC patients who may benefit from post-surgical systemic therapies.
Abstract: We have determined the expression of transforming growth factor alpha (TGF alpha), amphiregulin (AR), CRIPTO, the epidermal growth factor receptor (EGFR), erbB-2, erbB-3, and tumor angiogenesis in a series of 195 patients with stage I-IIIA non-small cell lung cancer (NSCLC) treated with radical surgery to define their usefulness as prognostic indicators of survival. A variable degree of specific staining in cancer cells was observed for the three growth factors and for the three growth factor receptors in the majority of NSCLC patients. A statistically significant association between overexpression of TGF alpha, AR, and CRIPTO was observed. Enhanced expression of AR was significantly correlated with enhanced expression of erbB-2 and advanced T-stage. A direct association was also detected for overexpression of TGF alpha and of erbB-2 or erbB-3, respectively. Sex, tumor size, nodal status, stage, microvessel count, as a measure of neovascularization, and AR overexpression significantly correlated with overall survival at univariate analysis. In a Cox multivariate analysis, the only characteristics with an independent prognostic effect on OAS were microvessel count [relative hazard (RH), 6.61; P < 0.00001), nodal status (RH, 1.59; P = 0.0013), and AR overexpression (RH, 1.72; P = 0.02). These results suggest that evaluation of neoangiogenesis and of certain growth factors, such as AR, can be useful in addition to conventional pathological staging to select high-risk NSCLC patients who may benefit from post-surgical systemic therapies.

314 citations

Journal ArticleDOI
TL;DR: The relationship between tumor angiogenesis and survival for 407 patients with non-small-cell lung carcinoma who were treated with potentially curative surgery and in identifying subsets of patients who may benefit from different postsurgical treatments was evaluated.
Abstract: Background: Tumors acquire nutrients that are essential for continued growth and an avenue for dissemination to the rest of the body by inducing angiogenesis (i.e., the formation of new blood vessels). Preliminary studies involving a number of different kinds of cancer have indicated that an assessment of tumor angiogenesis may be useful in predicting disease outcome. Purpose: In a prospective study, we evaluated the relationship between tumor angiogenesis and survival for 407 patients with non-small-cell lung carcinoma who were treated with potentially curative surgery. Methods: The study population consisted of 360 male and 47 female patients who underwent surgery consecutively at the Department of Surgery, University of Pisa, Italy, from March 1991 through December 1994. Follow-up lasted through February 1996, with a median follow-up for living patients of 29 months (range, 15-60 months). An anti-CD34 monoclonal antibody, which is specific for endothelial cells, and standard immunohistochemical techniques were used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel counts; the counts for single, high- power microscopic fields (magnification x250) in the three most intense areas of blood vessel growth for each sample were averaged. The median microvessel count in this series was 20, and the counts were categorized as follows : 1) low versus high (≤20 versus >20 microvessels) or 2) in five categories (1-10, 11-20, 21-30, 31-40, and ≥41 microvessels). Disease-free and overall survival during follow-up were assessed. Kaplan-Meier survival curves were modeled in a univariate analysis of patient and tumor characteristics; the Cox proportional hazards model was used in multivariate analysis. Reported P values are two-sided. Results and Conclusions: In the univariate analysis, patients with larger tumors (P for trend <.00001), a more advanced tumor stage (P for trend <.00001), a greater degree of regional lymph node involvement (P for trend <.00001), or more vascularized tumors (high versus low microvessel count, P<.00001) experienced significantly reduced overall survival. When microvessel counts were analyzed in five categories, a highly significant trend (P<.00001) toward worse prognosis was observed with increasing tumor vascularity. In multivariate analysis, tumor microvessel count (P<.00001), tumor size (P = .0006), and regional lymph node status (P<.00001) retained independent prognostic value with respect to overall survival; among these variables, tumor microvessel count, considered as a continuous variable, was the most important, with a relative hazard of death of 8.38 (95% confidence interval = 4.19-16.78) associated with the highest microvessel counts. Implications: An evaluation of tumor angiogenesis may be useful in the postsurgical staging of patients with non-small-cell lung carcinoma and in identifying subsets of patients who may benefit from different postsurgical treatments.

305 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Abstract: Patients with stage IIIB or IV non–small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center, performance status, response to prior chemotherapy, number of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo. results The median age of the 731 patients who underwent randomization was 61.4 years; 49 percent had received two prior chemotherapy regimens, and 93 percent had received platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group and less than 1 percent in the placebo group (P<0.001); the median duration of the response was 7.9 months and 3.7 months, respectively. Progression-free survival was 2.2 months and 1.8 months, respectively (hazard ratio, 0.61, adjusted for stratification categories; P<0.001). Overall survival was 6.7 months and 4.7 months, respectively (hazard ratio, 0.70; P<0.001), in favor of erlotinib. Five percent of patients discontinued erlotinib because of toxic effects. conclusions Erlotinib can prolong survival in patients with non–small-cell lung cancer after firstline or second-line chemotherapy.

5,157 citations

Journal ArticleDOI
Peter Goldstraw1, Kari Chansky, John Crowley, Ramón Rami-Porta2, Hisao Asamura3, Wilfried Ernst Erich Eberhardt4, Andrew G. Nicholson1, Patti A. Groome5, Alan Mitchell, Vanessa Bolejack, David Ball6, David G. Beer7, Ricardo Beyruti8, Frank C. Detterbeck9, Wilfried Eberhardt4, John G. Edwards10, Françoise Galateau-Salle11, Dorothy Giroux12, Fergus V. Gleeson13, James Huang14, Catherine Kennedy15, Jhingook Kim16, Young Tae Kim17, Laura Kingsbury12, Haruhiko Kondo18, Mark Krasnik19, Kaoru Kubota20, Antoon Lerut21, Gustavo Lyons, Mirella Marino, Edith M. Marom22, Jan P. van Meerbeeck23, Takashi Nakano24, Anna K. Nowak25, Michael D Peake26, Thomas W. Rice27, Kenneth E. Rosenzweig28, Enrico Ruffini29, Valerie W. Rusch14, Nagahiro Saijo, Paul Van Schil23, Jean-Paul Sculier30, Lynn Shemanski12, Kelly G. Stratton12, Kenji Suzuki31, Yuji Tachimori32, Charles F. Thomas33, William D. Travis14, Ming-Sound Tsao34, Andrew T. Turrisi35, Johan Vansteenkiste21, Hirokazu Watanabe, Yi-Long Wu, Paul Baas36, Jeremy J. Erasmus22, Seiki Hasegawa24, Kouki Inai37, Kemp H. Kernstine38, Hedy L. Kindler39, Lee M. Krug14, Kristiaan Nackaerts21, Harvey I. Pass40, David C. Rice22, Conrad Falkson5, Pier Luigi Filosso29, Giuseppe Giaccone41, Kazuya Kondo42, Marco Lucchi43, Meinoshin Okumura44, Eugene H. Blackstone27, F. Abad Cavaco, E. Ansótegui Barrera, J. Abal Arca, I. Parente Lamelas, A. Arnau Obrer45, R. Guijarro Jorge45, D. Ball6, G.K. Bascom46, A. I. Blanco Orozco, M. A. González Castro, M.G. Blum, D. Chimondeguy, V. Cvijanovic47, S. Defranchi48, B. de Olaiz Navarro, I. Escobar Campuzano2, I. Macía Vidueira2, E. Fernández Araujo49, F. Andreo García49, Kwun M. Fong, G. Francisco Corral, S. Cerezo González, J. Freixinet Gilart, L. García Arangüena, S. García Barajas50, P. Girard, Tuncay Göksel, M. T. González Budiño51, G. González Casaurrán50, J. A. Gullón Blanco, J. Hernández Hernández, H. Hernández Rodríguez, J. Herrero Collantes, M. Iglesias Heras, J. M. Izquierdo Elena, Erik Jakobsen, S. Kostas52, P. León Atance, A. Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles53, L. De Esteban Júlvez53, M. Mariñán Gorospe, Brian C. McCaughan15, Catherine J. Kennedy15, R. Melchor Íñiguez54, L. Miravet Sorribes, S. Naranjo Gozalo, C. Álvarez de Arriba, M. Núñez Delgado, J. Padilla Alarcón, J. C. Peñalver Cuesta, Jongsun Park16, H. Pass40, M. J. Pavón Fernández, Mara Rosenberg, Enrico Ruffini29, V. Rusch14, J. Sánchez de Cos Escuín, A. Saura Vinuesa, M. Serra Mitjans, Trond Eirik Strand, Dragan Subotic, S.G. Swisher22, Ricardo Mingarini Terra8, Charles R. Thomas33, Kurt G. Tournoy55, P. Van Schil23, M. Velasquez, Y.L. Wu, K. Yokoi 
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.

2,826 citations

Journal ArticleDOI
TL;DR: Recently, an anti-VEGF antibody (bevacizumab), when used in combination with chemotherapy, was shown to significantly improve survival and response rates in patients with metastatic colorectal cancer and thus, validate VEGF pathway inhibitors as an important new treatment modality in cancer therapy.
Abstract: New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor growth and metastatic dissemination. Hence, the molecular basis of tumor angiogenesis has been of keen interest in the field of cancer research. The vascular endothelial growth factor (VEGF) pathway is well established as one of the key regulators of this process. The VEGF/ VEGF-receptor axis is composed of multiple ligands and receptors with overlapping and distinct ligand-receptor binding specificities, cell-type expression, and function. Activation of the VEGF-receptor pathway triggers a network of signaling processes that promote endothelial cell growth, migration, and survival from pre-existing vasculature. In addition, VEGF mediates vessel permeability, and has been associated with malignant effusions. More recently, an important role for VEGF has emerged in mobilization of endothelial progenitor cells from the bone marrow to distant sites of neovascularization. The well-established role of VEGF in promoting tumor angiogenesis and the pathogenesis of human cancers has led to the rational design and development of agents that selectively target this pathway. Studies with various anti-VEGF/VEGF-receptor therapies have shown that these agents can potently inhibit angiogenesis and tumor growth in preclinical models. Recently, an anti-VEGF antibody (bevacizumab), when used in combination with chemotherapy, was shown to significantly improve survival and response rates in patients with metastatic colorectal cancer and thus, validate VEGF pathway inhibitors as an important new treatment modality in cancer therapy.

2,699 citations

Journal ArticleDOI
24 Jan 2018-Nature
TL;DR: Continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Abstract: Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

2,410 citations